BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2014)

24 slides from BioSpecifics Technologies's investor presentation, Mar 10, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE te ; BioSpecifics March 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Corporate Overview

    Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company developing injectable collagenase marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU XIAFLEX is now marketed for two indications in the U.S. by strategic partner, Aux

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture* Froze

  5. Slide 5: Recent Success Across All Indications

    Recent Success Across All Indications XIAFLEX was approved to be the first and only biologic therapy for the treatment of Peyronie’s disease in men with a palpable plaque and curvature of 30 degrees or greater at the start of therapy BioSpecifics reported data from proprietary pipeline in all three

  6. Slide 6: Approved Indications for XIAFLEX

    Approved Indications for XIAFLEX Phase 1 Phase 2 Phase 3 Marketed 1 Dupuytren’s PDUFA date in 4Q14 for FDA to review sBLA for multi-cord label Contracture Peyronie’s : Sobi to file MAA for approval in EU Disease fi SOLE

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand that causes one or more fingers to Definition and contract toward the palm, limiting range of motion of the fingers Key Complications Often results in physical disability, significantly affecting quality of life and daily a

  8. Slide 8: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Decision Expected in 4Q14 on Label Expansion = PDUFA date is October 20, 2014 for FDA to decide on sBLA, submitted by Auxilium, for XIAFLEX label expansion to allow multiple concurrent injections into same hand Pre-treatment: sBLA based on positive top-line data r

  9. Slide 9: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity, which can result in pain with erection, penile shortening, indentations, erectile Definition & ldyetanction and ondifficuty witli eexudl intercourse = Inseverecases penis Key Complications can bend at 90

  10. Slide 10: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Label Consistent with IMPRESS Trials Eee 2A. inca fore restment of aout men th Peyronie nese th ‘babe plague and carat dforiy of a east 0 daroos te tat of eran For men with Peyronie's disease, there's good news: the only FDA-approved treatment option. XIAFLEX XIAFLEX i

  11. Slide 11: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Initial Launch Progres: Focused, disciplined product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (surgery or verapamil injections ) 400 physicians performed about 90% of surgeries Initial target is top ~225 of these physicia

  12. Slide 12: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs dats] eclial| Pnet | rez [Paves | rata | Frozen Shoulder To} e data expected in 1Q1. *Human x= teem Initiate placebo-controlled trial in 2Q14 Cellulite Top-line data expected in 1Q15 *Uterine Fibroids *Canine 5 s 7 gonna Chien-804 final study report in 1Q14 Nata expected in

  13. Slide 13: CCH for Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition and the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans. Can be a serious health problem in do

  14. Slide 14: CCH for Canine Lipomas

    CCH for Canine Lipomas Chien-804 Placebo-Controlled Phase 2 Trial BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in dogs with benign subcutaneous lipomas 37 dogs randomized, single injection 1:1 CCH to placebo Primary efficacy endpoint: Relative change in lipoma

  15. Slide 15: CCH for Human Lipomas

    CCH for Human Lipomas Dose Escalation Phase 2 Clinical Trial BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas 14 patients received single injections of one of four ascending dosage groups ranging from 0.058 mg to 0.44 mg CCH Primar

  16. Slide 16: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Data Expected from Preclinical Studies in 2Q14 Definition & Key Complications Potential to be Nonsurgical Therapy Option U.S. Market Opportunity Preclinical Studies Ongoing Benign tumors with significant co- morbidities, which can include pain, decreased fertility, increased

  17. Slide 17: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Definition and Key Complications Potential to be Only Approved Nonsurgical Therapy Market Opportunity Top-line Data from Phase 2b Study Expected in 1Q15 Source: Auxilium Pharmaceuticals, Inc. Inflammation and thicken

  18. Slide 18: Frozen Shoulder — Statistically Significant

    Frozen Shoulder — Statistically Significant CCH Dose Response in Phase 2a Study 2 3 T 1 Forward Flexion Shoulder Abduction | External Rotation <0 05 Comparis 50. to Exercise Cohan jay < 6 Internal Rotation pS 3 8 Change from Baseline (Degrees) CCH Source: Auxilium Pharmaceuticals, Inc. Both the 0.58

  19. Slide 19: CCH for Cellulite

    CCH for Cellulite Top-line Data from Phase 2a Study Expected in 1Q Definiti Skin dimpling as a result of collagen fibrous septae held in an irregular pattern efinition under the skin, occurring mainly on the buttocks, lower limbs, and abdomen Significant Market z Affects 85-98% of women (est.) and r

  20. Slide 20: Auxilium Partnership

    Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of CCH >$40M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Royalties and Milestone Payment from Second Indication Auxilium Opt-in Rights Milestone Payments from AUXL Part

  21. Slide 21: Corporate Highlights

    Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 » Peyronie’s Disease: Aux

  22. Slide 22: Consistently Profitable Annually

    Consistently Profitable Annually 2013 Financial Highlights Cash and equivalents, short term investments Income Statement Revenues Other income Costs and expenses Provision for income taxes Net income Net income per basic share Net income per diluted share Shares used in computation of basic net inco

  23. Slide 23: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Q Initiate placebo-controlled trial in 1H14 Lipomas QO Complete enrollment in placebo-controlled trial in 4Q14 *Canine Q Chien-804 final study report in 1Q14 Bbenes O Final report triggers

  24. Slide 24: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE

Biospecifics Technologies — Investor Presentation (March 2014) on 6ix